Understanding how type I interferons are produced in lupus
Official title: Upstream drivers of type I interferons in lupus
Funded at University of Washington · NIH-11096045 · Data updated 2026-11-12
This study is looking at why some people with lupus have high levels of certain proteins in their immune system, by comparing their immune cells to those of healthy people, to help us better understand what causes lupus symptoms and flare-ups.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | May 28, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $758,431 |
| NIH project number | 5R01AI186337-02 |
| Project ID | NIH-11096045 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus, particularly those experiencing chronic symptoms.
✕Less likely to help
Patients without a diagnosis of systemic lupus erythematosus or those with other autoimmune conditions may not benefit from this research.
What this research studies
This research investigates the mechanisms behind the chronic production of type I interferons in patients with systemic lupus erythematosus (SLE). By analyzing immune cells such as neutrophils and monocytes from SLE patients and comparing them to healthy individuals, the researchers aim to identify the triggers that lead to interferon production. The study employs advanced technologies, including ultrasensitive protein detection and nucleic acid sequencing, to gather detailed insights into the molecular pathways involved. This comprehensive approach could significantly enhance our understanding of lupus and its flares.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing lupus and reducing disease flares.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in lupus, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Mustelin, Tomas M — University of Washington
- Study coordinator: Mustelin, Tomas M
Related research
Other NIH-funded projects on the same topics.
-
Understanding how DIS3L2 helps keep RNA in check to help lupus patients
A physician-scientist team is studying how a watchdog molecule for RNA (DIS3L2) may drive lupus-related immune problems, with the goal of uncovering new paths to treatment.
-
Pathogenic T cells in discoid lupus erythematosus
A doctor-scientist at Yale is studying why certain immune T cells cause skin damage in discoid lupus, with the goal of finding ways to reduce scarring and improve health for patients, especially African American women.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Antiviral factors that limit HIV in people with SLE
Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.